ViiV Healthcare's Long-Acting Cabenuva for HIV Demonstrates Superior Efficacy Compared to Daily Oral Therapy for People With Adherence Challenges; Results Published in NEJM
February 19, 2026
February 19, 2026
LONDON, England, Feb. 19 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
- Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological fa . . .
* * *
ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
- Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological fa . . .